The role of osteopontin in tumor metastasis

Journal of Surgical Research

Volumn 121, Issue 2, 2004, Pages 228-241

  Wai, Philip Y ^a   Kuo, Paul C ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

cancer; metastasis; osteopontin; transcription

Indexed keywords

HERMES ANTIGEN; INTEGRIN; ISOPROTEIN; OSTEOPONTIN;

ARTICLE; CANCER INVASION; CELL ACTIVITY; CELL INTERACTION; CELL SURFACE; CORRELATION ANALYSIS; DISEASE ACTIVITY; EXTRACELLULAR MATRIX; HUMAN; METASTASIS; MOLECULAR BIOLOGY; MOLECULAR DYNAMICS; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR GROWTH; UPREGULATION;

EID: 6344258588     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jss.2004.03.028     Document Type: Review

References (209)

1. D.R. Senger, D.F. Wirth, R.O. Hynes Transformed mammalian cells secrete specific proteins and phosphoproteins Cell 16 4 1979 885
2. L.W. Fisher, G.R. Hawkins, N. Tuross, J.D. Termine Purification and partial characterization of small proteoglycans I and II, bone sialoproteins I and II, and osteonectin from the mineral compartment of developing human bone J. Biol. Chem. 262 20 1987 9702
3. M.C. Kiefer, D.M. Bauer, P.J. Barr The cDNA and derived amino acid sequence for human osteopontin Nucleic Acids Res. 17 8 1989 3306
4. M.F. Young, J.M. Kerr, J.D. Termine, U.M. Wewer, M.G. Wang, O.W. McBride, L.W. Fisher cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN) Genomics 7 4 1990 491
5. J.L. Wrana, Q. Zhang, J. Sodek Full length cDNA sequence of porcine secreted phosphoprotein-I (SPP-I, osteopontin) Nucleic Acids Res. 17 23 1989 10119
6. J.H. Smith, D.T. Denhardt Molecular cloning of a tumor promoter-inducible mRNA found in JB6 mouse epidermal cells induction is stable at high, but not at low, cell densities J. Cell. Biochem. 34 1 1987 13
7. A.M. Craig, M. Nemir, B.B. Mukherjee, A.F. Chambers, D.T. Denhardt Identification of the major phosphoprotein secreted by many rodent cell lines as 2ar/osteopontin enhanced expression in H-ras-transformed 3T3 cells Biochem. Biophys. Res. Commun. 157 1 1988 166
8. H. Shiraga, W. Min, W.J. VanDusen, M.D. Clayman, D. Miner, C.H. Terrell, J.R. Sherbotie, J.W. Foreman, C. Przysiecki, E.G. Neilson Inhibition of calcium oxalate crystal growth in vitro by uropontin another member of the aspartic acid-rich protein superfamily Proc. Natl. Acad. Sci. USA 89 1 1992 426
9. R. Patarca, G.J. Freeman, R.P. Singh, F.Y. Wei, T. Durfee, F. Blattner, D.C. Regnier, C.A. Kozak, B.A. Mock, H.C. Morse 3rd Structural and functional studies of the early T lymphocyte activation 1 (Eta-1) gene. Definition of a novel T cell-dependent response associated with genetic resistance to bacterial infection J. Exp. Med. 170 1 1989 145
10. A.M. Craig, D.T. Denhardt The murine gene encoding secreted phosphoprotein 1 (osteopontin) promoter structure, activity, and induction in vivo by estrogen and progesterone Gene 100 1991 163
11. D.T. Denhardt, X. Guo Osteopontin a protein with diverse functions FASEB J. 7 15 1993 1475
12. D.R. Senger, C.A. Perruzzi, A. Papadopoulos-Sergiou, L. Van de Water Adhesive properties of osteopontin regulation by a naturally occurring thrombin-cleavage in close proximity to the GRGDS cell-binding domain Mol. Biol. Cell. 5 5 1994 565
13. M.G. Attur, M.N. Dave, S. Stuchin, A.J. Kowalski, G. Steiner, S.B. Abramson, D.T. Denhardt, A.R. Amin Osteopontin an intrinsic inhibitor of inflammation in cartilage Arthritis Rheum. 44 2001 578
14. H. Guo, C.Q. Cai, R.A. Schroeder, P.C. Kuo Osteopontin is a negative feedback regulator of nitric oxide synthesis in murine macrophages J. Immunol 166 2001 1079
15. R.J. Johnson, K.L. Gordon, C. Giachelli, T. Kurth, M.M. Skelton, A.W. Cowley Tubulointerstitial injury and loss of nitric oxide synthases parallel the development of hypertension in the Dahl-SS rat J. Hypertens. 18 2000 1497
16. B.S. Noble, J. Reeve Osteocyte function, osteocyte death and bone fracture resistance Mol. Cell Endocrinol. 159 2000 7
17. J.A. Scott, M.L. Weir, S.M. Wilson, J.W. Xuan, A.F. Chambers, D.G. McCormack Osteopontin inhibits inducible nitric oxide synthase activity in rat vascular tissue Am. J. Physiol. 275 1998 H2258
18. S.E. Thomas, D. Lombardi, C. Giachelli, A. Bohle, R.J. Johnson Osteopontin expression, tubulointerstitial disease, and essential hypertension Am. J. Hypertens. 11 1998 954
19. E.E. Rollo, D.L. Laskin, D.T. Denhardt Osteopontin inhibits nitric oxide production and cytotoxicity by activated RAW264.7 macrophages J. Leukoc. Biol. 60 1996 397
20. K. Singh, J.L. Balligand, T.A. Fischer, T.W. Smith, R.A. Kelly Glucocorticoids increase osteopontin expression in cardiac myocytes and microvascular endothelial cells. Role in regulation of inducible nitric oxide synthase J. Biol. Chem. 270 1995 28471
21. B. Feng, E.E. Rollo, D.T. Denhardt Osteopontin (OPN) may facilitate metastasis by protecting cells from macrophage NO-mediated cytotoxicity evidence from cell lines down-regulated for OPN expression by a targeted ribozyme Clin. Exp. Metastasis 13 1995 453
22. D.T. Denhardt, C.A. Lopez, E. Rollo Hwang, S. M., An, X. R., and Walther, S. E. Osteopontin-induced modifications of cellular functions Ann. NY Acad. Sci. 760 1995 127
23. S.M. Hwang, P.D. Wilson, J.D. Laskin, D.T. Denhardt Age and development-related changes in osteopontin and nitric oxide synthase mRNA levels in human kidney proximal tubule epithelial cells contrasting responses to hypoxia and reoxygenation J. Cell Physiol. 160 1994 61
24. S.M. Hwang, C.A. Lopez, D.E. Heck, C.R. Gardner, D.L. Laskin, J.D. Laskin, D.T. Denhardt Osteopontin inhibits induction of nitric oxide synthase gene expression by inflammatory mediators in mouse kidney epithelial cells J. Biol. Chem. 269 1994 711
25. N. Hijiya, M. Setoguchi, K. Matsuura, Y. Higuchi, S. Akizuki, S. Yamamoto Cloning and characterization of the human osteopontin gene and its promoter Biochem. J. 303 1994 255
26. D.T. Denhardt, M. Noda Osteopontin expression and function role in bone remodeling J. Cell. Biochem. Suppl. 30-31 1998 92
27. A. O'Regan, J.S. Berman Osteopontin a key cytokine in cell-mediated and granulomatous inflammation Int. J. Exp. Pathol. 81 6 2000 373
28. G.F. Weber The metastasis gene osteopontin a candidate target for cancer therapy Biochim. Biophys. Acta 1552 2 2001 61
29. D.R. Senger, C.A. Perruzzi, C.F. Gracey, A. Papadopoulos, D.G. Tenen Secreted phosphoproteins associated with neoplastic transformation close homology with plasma proteins cleaved during blood coagulation Cancer Res. 48 20 1988 5770
30. D.R. Senger, C.A. Perruzzi, A. Papadopoulos, D.G. Tenen Purification of a human milk protein closely similar to tumor-secreted phosphoproteins and osteopontin Biochim. Biophys. Acta 996 1-2 1989 43
31. D.S. Bautista, J. Denstedt, A.F. Chambers, J.F. Harris Low-molecular-weight variants of osteopontin generated by serine proteinases in urine of patients with kidney stones J. Cell. Biochem. 61 3 1996 402
32. R. Patarca, R.A. Saavedra, H. Cantor Molecular and cellular basis of genetic resistance to bacterial infection the role of the early T-lymphocyte activation-1/osteopontin gene Crit. Rev. Immunol. 13 3-4 1993 225
33. E.I. Behrend, A.F. Chambers, S.M. Wilson, D.T. Denhardt Comparative analysis of two alternative first exons reported for the mouse osteopontin gene J. Biol. Chem. 268 15 1993 11172
34. S. Yamamoto, N. Hijiya, M. Setoguchi, K. Matsuura, T. Ishida, Y. Higuchi, S. Akizuki Structure of the osteopontin gene and its promoter Ann. NY Acad. Sci. 760 1995 44
35. A. Franzen, D. Heinegard Isolation and characterization of two sialoproteins present only in bone calcified matrix Biochem. J. 232 3 1985 715
36. A. Oldberg, A. Franzen, D. Heinegard Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence Proc. Natl. Acad. Sci. USA 83 23 1986 8819
37. Y. Saitoh, J. Kuratsu, H. Takeshima, S. Yamamoto, Y. Ushio Expression of osteopontin in human glioma. Its correlation with the malignancy Lab. Invest. 72 1 1995 55
38. D.R. Senger, B.B. Asch, B.D. Smith, C.A. Perruzzi, H.F. Dvorak A secreted phosphoprotein marker for neoplastic transformation of both epithelial and fibroblastic cells Nature 302 5910 1983 714
39. D.R. Senger, C.A. Perruzzi Cell migration promoted by a potent GRGDS-containing thrombin-cleavage fragment of osteopontin Biochim. Biophys. Acta 1314 1-2 1996 13
40. D.R. Senger, C.A. Perruzzi Secreted phosphoprotein markers for neoplastic transformation of human epithelial and fibroblastic cells Cancer Res. 45 11 Pt 2 1985 5818
41. S. Ashkar, G.F. Weber, V. Panoutsakopoulou, M.E. Sanchirico, M. Jansson, S. Zawaideh, S.R. Rittling, D.T. Denhardt, M.J. Glimcher, H. Cantor Eta-1 (osteopontin) an early component of type-1 (cell-mediated) immunity Science 287 5454 2000 860
42. O. Helluin, C. Chan, G. Vilaire, S. Mousa, W.F. DeGrado, J.S. Bennett The activation state of alphavbeta 3 regulates platelet and lymphocyte adhesion to intact and thrombin-cleaved osteopontin J. Biol. Chem. 275 24 2000 18337
43. D.T. Denhardt, M. Noda, A.W. O'Regan, D. Pavlin, J.S. Berman Osteopontin as a means to cope with environmental insults regulation of inflammation, tissue remodeling, and cell survival J. Clin. Invest. 107 9 2001 1055
44. L.L. Smith, C.M. Giachelli Structural requirements for alpha 9 beta 1-mediated adhesion and migration to thrombin-cleaved osteopontin Exp. Cell Res. 242 1 1998 351
45. L.L. Smith, H.K. Cheung, L.E. Ling, J. Chen, D. Sheppard, R. Pytela, C.M. Giachelli Osteopontin N-terminal domain contains a cryptic adhesive sequence recognized by alpha9beta1 integrin J. Biol. Chem. 271 45 1996 28485
46. Y. Yokosaki, N. Matsuura, T. Sasaki, I. Murakami, H. Schneider, S. Higashiyama, Y. Saitoh, M. Yamakido, Y. Taooka, D. Sheppard The integrin alpha(9)beta(1) binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin J. Biol. Chem. 274 51 1999 36328
47. F.G. Giancotti, E. Ruoslahti Integrin signaling Science 285 5430 1999 1028
48. L. Liaw, M. Almeida, C.E. Hart, S.M. Schwartz, C.M. Giachelli Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro Circ. Res. 74 2 1994 214
49. L. Liaw, V. Lindner, S.M. Schwartz, A.F. Chambers, C.M. Giachelli Osteopontin and beta 3 integrin are coordinately expressed in regenerating endothelium in vivo and stimulate Arg-Gly-Asp-dependent endothelial migration in vitro Circ. Res. 77 4 1995 665
50. L. Liaw, M.P. Skinner, E.W. Raines, R. Ross, D.A. Cheresh, S.M. Schwartz, C.M. Giachelli The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro J. Clin. Invest. 95 2 1995 713
51. T.L. Yue, P.J. McKenna, E.H. Ohlstein, M.C. Farach-Carson, W.T. Butler, K. Johanson, P. McDevitt, G.Z. Feuerstein, J.M. Stadel Osteopontin-stimulated vascular smooth muscle cell migration is mediated by beta 3 integrin Exp. Cell Res. 214 2 1994 459
52. D.D. Hu, E.C. Lin, N.L. Kovach, J.R. Hoyer, J.W. Smith A biochemical characterization of the binding of osteopontin to integrins alpha v beta 1 and alpha v beta 5 J. Biol. Chem. 270 44 1995 26232
53. K.J. Bayless, G.A. Meininger, J.M. Scholtz, G.E. Davis Osteopontin is a ligand for the alpha4beta1 integrin J. Cell. Sci. 111 Pt 9 1998 1165
54. S. Denda, L.F. Reichardt, U. Muller Identification of osteopontin as a novel ligand for the integrin alpha8 beta1 and potential roles for this integrin-ligand interaction in kidney morphogenesis Mol. Biol. Cell. 9 6 1998 1425
55. S.T. Barry, S.B. Ludbrook, E. Murrison, C.M. Horgan A regulated interaction between alpha5beta1 integrin and osteopontin Biochem. Biophys. Res. Commun. 267 3 2000 764
56. D.J. Gerber, P. Pereira, S.Y. Huang, C. Pelletier, S. Tonegawa Expression of alpha v and beta 3 integrin chains on murine lymphocytes Proc. Natl. Acad. Sci. USA 93 25 1996 14698
57. F.P. Reinholt, K. Hultenby, A. Oldberg, D. Heinegard Osteopontin - a possible anchor of osteoclasts to bone Proc. Natl. Acad. Sci. USA 87 12 1990 4473
58. R.P. Singh, R. Patarca, J. Schwartz, P. Singh, H. Cantor Definition of a specific interaction between the early T lymphocyte activation 1 (Eta-1) protein and murine macrophages in vitro and its effect upon macrophages in vivo J. Exp. Med. 171 6 1990 1931
59. J.S. Bennett, C. Chan, G. Vilaire, S.A. Mousa, W.F. DeGrado Agonist-activated alphavbeta3 on platelets and lymphocytes binds to the matrix protein osteopontin J. Biol. Chem. 272 13 1997 8137
60. Y. Hamada, K. Nokihara, M. Okazaki, W. Fujitani, T. Matsumoto, M. Matsuo, Y. Umakoshi, J. Takahashi, N. Matsuura Angiogenic activity of osteopontin-derived peptide SVVYGLR Biochem. Biophys. Res. Commun. 310 1 2003 153
61. H. Liapis, A. Flath, S. Kitazawa Integrin alpha V beta 3 expression by bone-residing breast cancer metastases Diagn. Mol. Pathol. 5 2 1996 127
62. A. Angelucci, C. Festuccia, G. D'Andrea, A. Teti, M. Bologna Osteopontin modulates prostate carcinoma invasive capacity through RGD-dependent upregulation of plasminogen activators Biol. Chem. 383 1 2002 229
63. K.A. Furger, A.L. Allan, S.M. Wilson, C. Hota, S.A. Vantyghem, C.O. Postenka, W. Al-Katib, A.F. Chambers, A.B. Tuck Beta(3) integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin Mol. Cancer Res. 1 11 2003 810
64. D.R. Senger, S.R. Ledbetter, K.P. Claffey, A. Papadopoulos-Sergiou, C.A. Peruzzi, M. Detmar Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin Am. J. Pathol. 149 1 1996 293
65. M. Scatena, M. Almeida, M.L. Chaisson, N. Fausto, R.F. Nicosia, C.M. Giachelli NF-kappaB mediates alphavbeta3 integrin-induced endothelial cell survival J. Cell. Biol. 141 4 1998 1083
66. P.C. Brooks, A.M. Montgomery, M. Rosenfeld, R.A. Reisfeld, T. Hu, G. Klier, D.A. Cheresh Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels Cell 79 7 1994 1157
67. W. Arap, R. Pasqualini, E. Ruoslahti Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model Science 279 5349 1998 377
68. K.J. Bayless, R. Salazar, G.E. Davis RGD-dependent vacuolation and lumen formation observed during endothelial cell morphogenesis in three-dimensional fibrin matrices involves the alpha(v)beta(3) and alpha(5)beta(1) integrins Am. J. Pathol. 156 5 2000 1673
69. V.W. Engleman, G.A. Nickols, F.P. Ross, M.A. Horton, D.W. Griggs, S.L. Settle, P.G. Ruminski, S.L. Teitelbaum A peptidomimetic antagonist of the alpha(v)beta3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo J. Clin. Invest. 99 9 1997 2284
70. H. Rabinowich, W.C. Lin, A. Amoscato, R.B. Herberman, T.L. Whiteside Expression of vitronectin receptor on human NK cells and its role in protein phosphorylation, cytokine production, and cell proliferation J. Immunol. 154 3 1995 1124
71. S. Goodison, V. Urquidi, D. Tarin CD44 cell adhesion molecules Mol. Pathol. 52 4 1999 189
72. G.F. Weber, S. Ashkar, M.J. Glimcher, H. Cantor Receptor-ligand interaction between CD44 and osteopontin (Eta-1) Science 271 5248 1996 509
73. Y.U. Katagiri, J. Sleeman, H. Fujii, P. Herrlich, H. Hotta, K. Tanaka, S. Chikuma, H. Yagita, K. Okumura, M. Murakami, I. Saiki, A.F. Chambers, T. Uede CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis Cancer Res. 59 1 1999 219
74. Z. Rudzki, S. Jothy CD44 and the adhesion of neoplastic cells Mol. Pathol. 50 2 1997 57
75. H. Ponta, L. Sherman, P.A. Herrlich CD44 from adhesion molecules to signaling regulators Nat. Rev. Mol. Cell Biol. 4 1 2003 33
76. K. Takahashi, F. Takahashi, M. Hirama, K.K. Tanabe, Y. Fukuchi Restoration of CD44S in non-small cell lung cancer cells enhanced their susceptibility to the macrophage cytotoxicity Lung Cancer 41 2 2003 145
77. K. Asosingh, U. Gunthert, M.H. Bakkus, H. De Raeve, E. Goes, I. Van Riet, B. Van Camp, K. Vanderkerken In vivo induction of insulin-like growth factor-I receptor and CD44v6 confers homing and adhesion to murine multiple myeloma cells Cancer Res. 60 11 2000 3096
78. U. Gunthert, M. Hofmann, W. Rudy, S. Reber, M. Zoller, I. Haussmann, S. Matzku, A. Wenzel, H. Ponta, P. Herrlich A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells Cell 65 1 1991 13
79. W. Rudy, M. Hofmann, R. Schwartz-Albiez, M. Zoller, K.H. Heider, H. Ponta, P. Herrlich The two major CD44 proteins expressed on a metastatic rat tumor cell line are derived from different splice variants each one individually suffices to confer metastatic behavior Cancer Res. 53 6 1993 1262
80. Y.H. Lin, C.J. Huang, J.R. Chao, S.T. Chen, S.F. Lee, J.J. Yen, H.F. Yang-Yen Coupling of osteopontin and its cell surface receptor CD44 to the cell survival response elicited by interleukin-3 or granulocyte-macrophage colony-stimulating factor Mol. Cell Biol. 20 8 2000 2734
81. C. Gao, H. Guo, L. Downey, C. Marroquin, J. Wei, P.C. Kuo Osteopontin-dependent CD44v6 expression and cell adhesion in HepG2 cells Carcinogenesis 24 12 2003 1871 Epub 2003 Aug 29
82. R. Zohar, S. Cheifetz, C.A. McCulloch, J. Sodek Analysis of intracellular osteopontin as a marker of osteoblastic cell differentiation and mesenchymal cell migration Eur. J. Oral Sci. 106 Suppl. 1 1998 401
83. R. Zohar, N. Suzuki, K. Suzuki, P. Arora, M. Glogauer, C.A. McCulloch, J. Sodek Intracellular osteopontin is an integral component of the CD44-ERM complex involved in cell migration J. Cell Physiol. 184 1 2000 118
84. J. Sodek, B. Ganss, M.D. McKee Osteopontin Crit. Rev. Oral Biol. Med. 11 3 2000 279
85. L.F. Brown, A. Papadopoulos-Sergiou, B. Berse, E.J. Manseau, K. Tognazzi, C.A. Perruzzi, H.F. Dvorak, D.R. Senger Osteopontin expression and distribution in human carcinomas Am. J. Pathol. 145 3 1994 610
86. A. Bellahcene, V. Castronovo Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer Am. J. Pathol. 146 1 1995 95
87. S. Hirota, A. Ito, J. Nagoshi, M. Takeda, A. Kurata, Y. Takatsuka, K. Kohri, S. Nomura, Y. Kitamura Expression of bone matrix protein messenger ribonucleic acids in human breast cancers. Possible involvement of osteopontin in development of calcifying foci Lab. Invest. 72 1 1995 64
88. H. Singhal, D.S. Bautista, K.S. Tonkin, F.P. O'Malley, A.B. Tuck, A.F. Chambers, J.F. Harris Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival Clin. Cancer Res. 3 4 1997 605
89. A.B. Tuck, F.P. O'Malley, H. Singhal, J.F. Harris, K.S. Tonkin, N. Kerkvliet, Z. Saad, G.S. Doig, A.F. Chambers Osteopontin expression in a group of lymph node negative breast cancer patients Int. J. Cancer 79 5 1998 502
90. A.G. Casson, S.M. Wilson, J.A. McCart, F.P. O'Malley, H. Ozcelik, M.S. Tsao, A.F. Chambers ras mutation and expression of the ras-regulated genes osteopontin and cathepsin L in human esophageal cancer Int. J. Cancer 72 5 1997 739
91. M. Gotoh, M. Sakamoto, K. Kanetaka, M. Chuuma, S. Hirohashi Overexpression of osteopontin in hepatocellular carcinoma Pathol. Int. 52 1 2002 19
92. N.S. Fedarko, A. Jain, A. Karadag, M.R. Van Eman, L.W. Fisher Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer Clin. Cancer Res. 7 12 2001 4060
93. A.B. Tuck, F.P. O'Malley, H. Singhal, K.S. Tonkin, J.F. Harris, D. Bautista, A.F. Chambers Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas Arch. Pathol. Lab. Med. 121 6 1997 578
94. A.B. Tuck, D.M. Arsenault, F.P. O'Malley, C. Hota, M.C. Ling, S.M. Wilson, A.F. Chambers Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells Oncogene 18 29 1999 4237
95. T. Ue, H. Yokozaki, Y. Kitadai, S. Yamamoto, W. Yasui, T. Ishikawa, E. Tahara Co-expression of osteopontin and CD44v9 in gastric cancer Int. J. Cancer 79 2 1998 127
96. N. Shijubo, T. Uede, S. Kon, M. Maeda, T. Segawa, A. Imada, M. Hirasawa, S. Abe Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma Am. J. Respir. Crit. Care Med. 160 4 1999 1269
97. A.F. Chambers, S.M. Wilson, N. Kerkvliet, F.P. O'Malley, J.F. Harris, A.G. Casson Osteopontin expression in lung cancer Lung Cancer 15 3 1996 311
98. G.N. Thalmann, R.A. Sikes, R.E. Devoll, J.A. Kiefer, R. Markwalder, I. Klima, C.M. Farach-Carson, U.E. Studer, L.W. Chung Osteopontin possible role in prostate cancer progression Clin. Cancer Res. 5 8 1999 2271
99. H.W. Pan, Y.H. Ou, S.Y. Peng, S.H. Liu, P.L. Lai, P.H. Lee, J.C. Sheu, C.L. Chen, H.C. Hsu Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma Cancer 98 1 2003 119
100. D. Agrawal, T. Chen, R. Irby, J. Quackenbush, A.F. Chambers, M. Szabo, A. Cantor, D. Coppola, T.J. Yeatman Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling J. Natl. Cancer Inst. 94 7 2002 513
101. T.J. Yeatman, A.F. Chambers Osteopontin and colon cancer progression Clin. Exp. Metastasis 20 1 2003 85
102. P.S. Rudland, A. Platt-Higgins, M. El-Tanani, S. De Silva Rudland, R. Barraclough, J.H. Winstanley, R. Howitt, C.R. West Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer Cancer Res. 62 12 2002 3417
103. A.B. Tuck, B.E. Elliott, C. Hota, E. Tremblay, A.F. Chambers Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met) J. Cell Biochem. 78 3 2000 465
104. T. Yoneda, P.J. Williams, M. Niewolna Promotion of angiogenesis and enhancement of breast cancer metastasis to bone Bone 23 5s 1998 201
105. A.J. Oates, R. Barraclough, P.S. Rudland The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model Oncogene 13 1 1996 97
106. H. Chen, Y. Ke, A.J. Oates, R. Barraclough, P.S. Rudland Isolation of and effector for metastasis-inducing DNAs from a human metastatic carcinoma cell line Oncogene 14 13 1997 1581
107. F. Takahashi, S. Akutagawa, H. Fukumoto, S. Tsukiyama, Y. Ohe, K. Takahashi, Y. Fukuchi, N. Saijo, K. Nishio Osteopontin induces angiogenesis of murine neuroblastoma cells in mice Int. J. Cancer 98 5 2002 707
108. Y. Wu, D.T. Denhardt, S.R. Rittling Osteopontin is required for full expression of the transformed phenotype by the ras oncogene Br. J. Cancer 83 2 2000 156
109. H. Nemoto, S.R. Rittling, H. Yoshitake, K. Furuya, T. Amagasa, K. Tsuji, A. Nifuji, D.T. Denhardt, M. Noda Osteopontin deficiency reduces experimental tumor cell metastasis to bone and soft tissues J. Bone Miner. Res. 16 4 2001 652
110. R. Mukhopadhyay, J.E. Price Stable expression of Antisense osteopontin inhibits the growth of human breast cancer cells Proc. Am. Assoc. Cancer Res. 40: 1999 448
111. H. Adwan, T.J. Bauerle, M.R. Berger Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells Cancer Gene Therapy 11 2004 109 Epub 2003 Nov 28.
112. H.A. Gardner, B. Berse, D.R. Senger Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts Oncogene 9 8 1994 2321
113. E.I. Behrend, A.M. Craig, S.M. Wilson, D.T. Denhardt, A.F. Chambers Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA Cancer Res. 54 3 1994 832
114. H.C. Crawford, L.M. Matrisian, L. Liaw Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo Cancer Res. 58 22 1998 5206
115. K.K. Tanabe, L.M. Ellis, H. Saya Expression of CD44R1 adhesion molecule in colon carcinomas and metastases Lancet 341 8847 1993 725
116. I. Stamenkovic, A. Aruffo, M. Amiot, B. Seed The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells EMBO J. 10 2 1991 343
117. Y. Matsumura, D. Tarin Significance of CD44 gene products for cancer diagnosis and disease evaluation Lancet 340 8827 1992 1053
118. Tanabe, K. K., Stamenkovic, I., Cutler, M., and Takahashi, K. Restoration of CD44H expression in colon carcinomas reduces tumorigenicity. Ann. Surg. 222(4): 493; discussion 501.
119. K. Takahashi, I. Stamenkovic, M. Cutler, H. Saya, K.K. Tanabe CD44 hyaluronate binding influences growth kinetics and tumorigenicity of human colon carcinomas Oncogene 11 11 1995 2223
120. G.I. Evan, K.H. Vousden Proliferation, cell cycle and apoptosis in cancer Nature 411 6835 2001 342
121. Y.H. Lin, H.F. Yang-Yen The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway J. Biol. Chem. 276 49 2001 46024 Epub 2001 Oct 05
122. K.A. Hruska, F. Rolnick, M. Huskey, U. Alvarez, D. Cheresh Engagement of the osteoclast integrin alpha v beta 3 by osteopontin stimulates phosphatidylinositol 3-hydroxyl kinase activity Endocrinology 136 7 1995 2984
123. M. Chellaiah, K. Hruska Osteopontin stimulates gelsolin-associated phosphoinositide levels and phosphatidylinositol triphosphate-hydroxyl kinase Mol. Biol. Cell. 7 5 1996 743
124. V. Urquidi, D. Sloan, K. Kawai, D. Agarwal, A.C. Woodman, D. Tarin, S. Goodison Contrasting expression of thrombospondin-1 and osteopontin correlates with absence or presence of metastatic phenotype in an isogenic model of spontaneous human breast cancer metastasis Clin. Cancer Res. 8 1 2002 61
125. S. Aznavoorian, A.N. Murphy, W.G. Stetler-Stevenson, L.A. Liotta Molecular aspects of tumor cell invasion and metastasis Cancer 71 4 1993 1368
126. G. Murphy, J. Gavrilovic Proteolysis and cell migration creating a path? Curr. Opin. Cell. Biol. 11 5 1999 614
127. S. Philip, A. Bulbule, G.C. Kundu Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells J. Biol. Chem. 276 48 2001 44926
128. A.B. Tuck, C. Hota, A.F. Chambers Osteopontin (OPN)-induced increase in human mammary epithelial cell invasiveness is urokinase (uPA)-dependent Breast Cancer Res. Treat. 70 3 2001 197
129. P.A. Andreasen, L. Kjoller, L. Christensen, M.J. Duffy The urokinase-type plasminogen activator system in cancer metastasis a review Int. J. Cancer 72 1 1997 1
130. J.L. Fisher, C.L. Field, H. Zhou, T.L. Harris, M.A. Henderson, P.F. Choong Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases - a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases Breast Cancer Res. Treat. 61 1 2000 1
131. S. Philip, G.C. Kundu Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha /IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways J. Biol. Chem. 278 16 2003 14487
132. R. Das, G.H. Mahabeleshwar, G.C. Kundu Osteopontin stimulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells J. Biol. Chem. 278 31 2003 28593
133. P. Friedl, K. Wolf Tumour-cell invasion and migration diversity and escape mechanisms Nat. Rev. Cancer 3 5 2003 362
134. A.B. Tuck, C. Hota, S.M. Wilson, A.F. Chambers Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways Oncogene 22 8 2003 1198
135. D.T. Denhardt, A.F. Chambers Overcoming obstacles to metastasis-defenses against host defenses osteopontin (OPN) as a shield against attack by cytotoxic host cells J. Cell. Biochem. 56 1 1994 48
136. C. Gao, H. Guo, J. Wei, P.C. Kuo Osteopontin inhibits expression of cytochrome c oxidase in RAW 264.7 murine macrophages Biochem. Biophys. Res. Commun. 309 1 2003 120
137. H. Guo, C.Q. Cai, R.A. Schroeder, P.C. Kuo Osteopontin is a negative feedback regulator of nitric oxide synthesis in murine macrophages J. Immunol. 166 2 2001 1079
138. J.A. Scott, M.L. Weir, S.M. Wilson, J.W. Xuan, A.F. Chambers, D.G. McCormack Osteopontin inhibits inducible nitric oxide synthase activity in rat vascular tissue Am. J. Physiol. 275 6 Pt. 2 1998 H2258
139. T. Nagasaki, E. Ishimura, H. Koyama, A. Shioi, S. Jono, M. Inaba, T. Hasuma, M. Yokoyama, Y. Nishizawa, H. Morii, S. Otani Alphav integrin regulates TNF-alpha-induced nitric oxide synthesis in rat mesangial cells - possible role of osteopontin Nephrol. Dial Transplant. 14 8 1999 1861
140. J. Folkman Role of angiogenesis in tumor growth and metastasis Semin. Oncol. 29 6 Suppl. 16 2002 15
141. V. Hanrahan, M.J. Currie, S.P. Gunningham, H.R. Morrin, P.A. Scott, B.A. Robinson, S.B. Fox The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression J. Pathol. 200 2 2003 183
142. Y. Nakamura, H. Yasuoka, M. Tsujimoto, Q. Yang, S. Imabun, M. Nakahara, K. Nakao, M. Nakamura, I. Mori, K. Kakudo Prognostic significance of vascular endothelial growth factor D in breast carcinoma with long-term follow-up Clin. Cancer Res. 9 2 2003 716
143. M. Hirama, F. Takahashi, K. Takahashi, S. Akutagawa, K. Shimizu, S. Soma, Y. Shimanuki, K. Nishio, Y. Fukuchi Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth Cancer Lett. 198 1 2003 107
144. D. Leali, P. Dell'Era, H. Stabile, B. Sennino, A.F. Chambers, A. Naldini, S. Sozzani, B. Nico, D. Ribatti, M. Presta Osteopontin (Eta-1) and fibroblast growth factor-2 cross-talk in angiogenesis J. Immunol. 171 2 2003 1085
145. S.A. Khan, C.A. Lopez-Chua, J. Zhang, L.W. Fisher, E.S. Sorensen, D.T. Denhardt Soluble osteopontin inhibits apoptosis of adherent endothelial cells deprived of growth factors J. Cell. Biochem. 85 4 2002 728
146. U.M. Malyankar, R. Hanson, S.M. Schwartz, A.L. Ridall, C.M. Giachelli Upstream stimulatory factor 1 regulates osteopontin expression in smooth muscle cells Exp. Cell Res. 250 2 1999 535
147. Q. Zhang, J.L. Wrana, J. Sodek Characterization of the promoter region of the porcine opn (osteopontin, secreted phosphoprotein 1) gene. Identification of positive and negative regulatory elements and a "silent" second promoter Eur. J. Biochem. 207 2 1992 649
148. R. Eferl, E.F. Wagner AP-1 a double-edged sword in tumorigenesis Nat Rev Cancer 3 11 2003 859
149. T. Deng, M. Karin JunB differs from c-Jun in its DNA-binding and dimerization domains, and represses c-Jun by formation of inactive heterodimers Genes Dev. 7 3 1993 479
150. R. Chiu, P. Angel, M. Karin Jun-B differs in its biological properties from, and is a negative regulator of, c-Jun Cell. 59 6 1989 979
151. Z.Q. Wang, A.E. Grigoriadis, U. Mohle-Steinlein, E.F. Wagner A novel target cell for c-fos-induced oncogenesis development of chondrogenic tumours in embryonic stem cell chimeras EMBO J. 10 9 1991 2437
152. A.E. Grigoriadis, K. Schellander, Z.Q. Wang, E.F. Wagner Osteoblasts are target cells for transformation in c-fos transgenic mice J. Cell Biol. 122 3 1993 685
153. M.R. Young, J.J. Li, M. Rincon, R.A. Flavell, B.K. Sathyanarayana, R. Hunziker, N. Colburn Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion Proc. Natl. Acad. Sci. USA 96 17 1999 9827
154. W. Jochum, J.P. David, C. Elliott, A. Wutz, H. Plenk Jr., K. Matsuo, E.F. Wagner Increased bone formation and osteosclerosis in mice overexpressing the transcription factor Fra-1 Nat. Med. 6 9 2000 980
155. M.A. Renault, S. Jalvy, I. Belloc, S. Pasquet, S. Sena, M. Olive, C. Desgranges, A.P. Gadeau AP-1 is involved in UTP-induced osteopontin expression in arterial smooth muscle cells Circ. Res. 93 7 2003 674
156. H.J. Kim, M.H. Lee, H.J. Kim, H.I. Shin, J.Y. Choi, H.M. Ryoo Okadaic acid stimulates osteopontin expression through de novo induction of AP-1 J. Cell. Biochem. 87 1 2002 93
157. D. Wang, S. Yamamoto, N. Hijiya, E.N. Benveniste, C.L. Gladson Transcriptional regulation of the human osteopontin promoter functional analysis and DNA-protein interactions Oncogene 19 50 2000 5801
158. A. Kiermaier, J.M. Gawn, L. Desbarats, R. Saffrich, W. Ansorge, P.J. Farrell, M. Eilers, G. Packham DNA binding of USF is required for specific E-box dependent gene activation in vivo Oncogene 18 51 1999 7200
159. M. Sirito, Q. Lin, J.M. Deng, R.R. Behringer, M. Sawadogo Overlapping roles and asymmetrical cross-regulation of the USF proteins in mice Proc. Natl. Acad. Sci. USA 95 7 1998 3758
160. W.R. Atchley, W.M. Fitch A natural classification of the basic helix-loop-helix class of transcription factors Proc. Natl. Acad. Sci. USA 94 10 1997 5172
161. A.S. Jaiswal, S. Narayan Upstream stimulating factor-1 (USF1) and USF2 bind to and activate the promoter of the adenomatous polyposis coli (APC) tumor suppressor gene J. Cell. Biochem. 81 2 2001 262
162. D. Reisman, V. Rotter The helix-loop-helix containing transcription factor USF binds to and transactivates the promoter of the p53 tumor suppressor gene Nucleic Acids Res. 21 2 1993 345
163. M. Bidder, J.S. Shao, N. Charlton-Kachigian, A.P. Loewy, C.F. Semenkovich, D.A. Towler Osteopontin transcription in aortic vascular smooth muscle cells is controlled by glucose-regulated upstream stimulatory factor and activator protein-1 activities J. Biol. Chem. 277 46 2002 44485
164. K. Tezuka, D.T. Denhardt, G.A. Rodan, S. Harada Stimulation of mouse osteopontin promoter by v-Src is mediated by a CCAAT box-binding factor J. Biol. Chem. 271 37 1996 22713
165. G.A. Blobel, H. Hanafusa The v-src inducible gene 9E3/pCEF4 is regulated by both its promoter upstream sequence and its 3′ untranslated region Proc. Natl. Acad. Sci. USA 88 4 1991 1162
166. A. Schonthal, P. Herrlich, H.J. Rahmsdorf, H. Ponta Requirement for fos gene expression in the transcriptional activation of collagenase by other oncogenes and phorbol esters Cell 54 3 1988 325
167. M.C. Birchenall-Roberts, F.W. Ruscetti, J. Kasper, H.D. Lee, R. Friedman, A. Geiser, M.B. Sporn, A.B. Roberts, S.J. Kim Transcriptional regulation of the transforming growth factor beta 1 promoter by v-src gene products is mediated through the AP-1 complex Mol. Cell Biol. 10 9 1990 4978
168. M. Fujii, D. Shalloway, I.M. Verma Gene regulation by tyrosine kinases src protein activates various promoters, including c-fos Mol. Cell Biol. 9 6 1989 2493
169. I. Apel, C.L. Yu, T. Wang, C. Dobry, M.E. Van Antwerp, R. Jove, E.V. Prochownik Regulation of the junB gene by v-src Mol. Cell Biol. 12 8 1992 3356
170. H. Sato, M. Kita, M. Seiki v-Src activates the expression of 92-kDa type IV collagenase gene through the AP-1 site and the GT box homologous to retinoblastoma control elements. A mechanism regulating gene expression independent of that by inflammatory cytokines J. Biol. Chem. 268 31 1993 23460
171. A.H. Lund, M. van Lohuizen RUNX a trilogy of cancer genes Cancer Cell 1 3 2002 213
172. J.A. Coffman 2003. Runx transcription factors and the developmental balance between cell proliferation and differentiation Cell Biol. Int. 27 4 2003 315
173. Y. Ito, K. Miyazono RUNX transcription factors as key targets of TGF-beta superfamily signaling Curr. Opin. Genet. Dev. 13 1 2003 43
174. Q.L. Li, K. Ito, C. Sakakura, H. Fukamachi, K. Inoue, X.Z. Chi, K.Y. Lee, S. Nomura, C.W. Lee, S.B. Han, H.M. Kim, W.J. Kim, H. Yamamoto, N. Yamashita, T. Yano, T. Ikeda, S. Itohara, J. Inazawa, T. Abe, A. Hagiwara, H. Yamagishi, A. Ooe, A. Kaneda, T. Sugimura, T. Ushijima, S.C. Bae, Y. Ito Causal relationship between the loss of RUNX3 expression and gastric cancer Cell 109 1 2002 113
175. N.A. Speck, D.G. Gilliland Core-binding factors in haematopoiesis and leukaemia Nat. Rev. Cancer 2 7 2002 502
176. C.K. Inman, P. Shore The osteoblast transcription factor Runx2 is expressed in mammary epithelial cells and mediates osteopontin expression J. Biol/ Chem. 278 49 2003 48684 Epub 2003 Sep 23
177. F. Otto, A.P. Thornell, T. Crompton, A. Denzel, K.C. Gilmour, I.R. Rosewell, G.W. Stamp, R.S. Beddington, S. Mundlos, B.R. Olsen, P.B. Selby, M.J. Owen Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development Cell 89 5 1997 765
178. T. Komori, H. Yagi, S. Nomura, A. Yamaguchi, K. Sasaki, K. Deguchi, Y. Shimizu, R.T. Bronson, Y.H. Gao, M. Inada, M. Sato, R. Okamoto, Y. Kitamura, S. Yoshiki, T. Kishimoto Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts Cell 89 5 1997 755
179. M. Sato, E. Morii, T. Komori, H. Kawahata, M. Sugimoto, K. Terai, H. Shimizu, T. Yasui, H. Ogihara, N. Yasui, T. Ochi, Y. Kitamura, Y. Ito, S. Nomura Transcriptional regulation of osteopontin gene in vivo by PEBP2alphaA/CBFA1 and ETS1 in the skeletal tissues Oncogene 17 12 1998 1517
180. G.L. Barnes, A. Javed, S.M. Waller, M.H. Kamal, K.E. Hebert, M.Q. Hassan, A. Bellahcene, A.J. Van Wijnen, M.F. Young, J.B. Lian, G.S. Stein, L.C. Gerstenfeld Osteoblast-related transcription factors Runx2 (Cbfa1/AML3) and MSX2 mediate the expression of bone sialoprotein in human metastatic breast cancer cells Cancer Res. 63 10 2003 2631
181. K.S. Lee, H.J. Kim, Q.L. Li, X.Z. Chi, C. Ueta, T. Komori, J.M. Wozney, E.G. Kim, J.Y. Choi, H.M. Ryoo, S.C. Bae Runx2 is a common target of transforming growth factor beta1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12 Mol. Cell Biol. 20 23 2000 8783
182. J. Hanai, L.F. Chen, T. Kanno, N. Ohtani-Fujita, W.Y. Kim, W.H. Guo, T. Imamura, Y. Ishidou, M. Fukuchi, M.J. Shi, J. Stavnezer, M. Kawabata, K. Miyazono, Y. Ito Interaction and functional cooperation of PEBP2/CBF with Smads. Synergistic induction of the immunoglobulin germline Calpha promoter J. Biol. Chem. 274 44 1999 31577
183. X. Shi, S. Bai, L. Li, X. Cao Hoxa-9 represses transforming growth factor-beta-induced osteopontin gene transcription J Biol Chem. 276 1 2001 850
184. A.B. Roberts, L.M. Wakefield The two faces of transforming growth factor beta in carcinogenesis Proc. Natl. Acad. Sci. USA 100 15 2003 8621
185. E.E. Medrano Repression of TGF-beta signaling by the oncogenic protein SKI in human melanomas consequences for proliferation, survival, and metastasis Oncogene 22 20 2003 3123
186. D. Bello-DeOcampo, D.J. Tindall TGF-betal/Smad signaling in prostate cancer Curr. Drug Targets 4 3 2003 197
187. T.A. Guise, J.M. Chirgwin Transforming growth factor-beta in osteolytic breast cancer bone metastases Clin. Orthop. 415 Suppl. 2003 S32
188. S.J. Kim, J. Letterio Transforming growth factor-beta signaling in normal and malignant hematopoiesis Leukemia 17 9 2003 1731
189. M. Noda, K. Yoon, C.W. Prince, W.T. Butler, G.A. Rodan Transcriptional regulation of osteopontin production in rat osteosarcoma cells by type beta transforming growth factor J. Biol. Chem. 263 27 1988 13916
190. J.L. Wrana, T. Kubota, Q. Zhang, C.M. Overall, J.E. Aubin, W.T. Butler, J. Sodek Regulation of transformation-sensitive secreted phosphoprotein (SPPI/osteopontin) expression by transforming growth factor-beta. Comparisons with expression of SPARC (secreted acidic cysteine-rich protein) Biochem. J. 273 Pt. 3 1991 523
191. S. Cheifetz, I.W. Li, C.A. McCulloch, K. Sampath, J. Sodek Influence of osteogenic protein-1 (OP-1;BMP-7) and transforming growth factor-beta 1 on bone formation in vitro Connect Tissue Res. 35 1-4 1996 71
192. T.G. Hullinger, Q. Pan, H.L. Viswanathan, M.J. Somerman TGFbeta and BMP-2 activation of the OPN promoter roles of smad- and hox-binding elements Exp. Cell Res. 262 1 2001 69
193. J. Cui, X. Zhou, Y. Liu, Z. Tang, M. Romeih Wnt signaling in hepatocellular carcinoma analysis of mutation and expression of beta-catenin, T-cell factor-4 and glycogen synthase kinase 3-beta genes J. Gastroenterol. Hepatol. 18 3 2003 280
194. R.M. Bright-Thomas, R. Hargest APC, beta-Catenin and hTCF-4; an unholy trinity in the genesis of colorectal cancer Eur. J. Surg. Oncol. 29 2 2003 107
195. M. El-Tanani, R. Barraclough, M.C. Wilkinson, P.S. Rudland Metastasis-inducing dna regulates the expression of the osteopontin gene by binding the transcription factor Tcf-4 Cancer Res. 61 14 2001 5619
196. D.T. Denhardt, D. Mistretta, A.F. Chambers, S. Krishna, J.F. Porter, S. Raghuram, S.R. Rittling Transcriptional regulation of osteopontin and the metastatic phenotype evidence for a Ras-activated enhancer in the human OPN promoter Clin. Exp. Metastasis 20 1 2003 77
197. J.L. Bos ras oncogenes in human cancer a review Cancer Res. 49 17 1989 4682
198. A.F. Chambers, E.I. Behrend, S.M. Wilson, D.T. Denhardt Induction of expression of osteopontin (OPN; secreted phosphoprotein) in metastatic, ras-transformed NIH 3T3 cells Anticancer Res. 12 1 1992 43
199. X. Guo, Y.P. Zhang, D.A. Mitchell, D.T. Denhardt, A.F. Chambers Identification of a ras-activated enhancer in the mouse osteopontin promoter and its interaction with a putative ETS-related transcription factor whose activity correlates with the metastatic potential of the cell Mol Cell Biol. 15 1 1995 476
200. I. Morimoto, Y. Sasaki, S. Ishida, K. Imai, T. Tokino Identification of the osteopontin gene as a direct target of TP53 Genes Chromosomes Cancer 33 3 2002 270
201. W.S. el-Deiry Regulation of p53 downstream genes Semin. Cancer Biol. 8 5 1998 345
202. T. Tokino, Y. Nakamura The role of p53-target genes in human cancer Crit. Rev. Oncol. Hematol. 33 1 2000 1
203. B. Vogelstein, D. Lane, A.J. Levine Surfing the p53 network Nature 408 6810 2000 307
204. K. Zhu, J. Wang, J. Zhu, J. Jiang, J. Shou, X. Chen p53 induces TAP1 and enhances the transport of MHC class I peptides Oncogene 18 54 1999 7740
205. A.M. Craig, G.T. Bowden, A.F. Chambers, M.A. Spearman, A.H. Greenberg, J.A. Wright, M. McLeod, D.T. Denhardt Secreted phosphoprotein mRNA is induced during multi-stage carcinogenesis in mouse skin and correlates with the metastatic potential of murine fibroblasts Int. J. Cancer 46 1 1990 133
206. P.L. Chang, M.A. Tucker, P.H. Hicks, C.W. Prince Novel protein kinase C isoforms and mitogen-activated kinase kinase mediate phorbol ester-induced osteopontin expression Int. J. Biochem. Cell. Biol. 34 9 2002 1142
207. S.S. Manji, K.W. Ng, T.J. Martin, H. Zhou Transcriptional and posttranscriptional regulation of osteopontin gene expression in preosteoblasts by retinoic acid J. Cell Physiol. 176 1 1998 1
208. S. Asaumi, M. Takemoto, K. Yokote, A.L. Ridall, W.T. Butler, M. Fujimoto, K. Kobayashi, H. Kawamura, A. Take, Y. Saito, S. Mori Identification and characterization of high glucose and glucosamine responsive element in the rat osteopontin promoter J. Diabetes Complications 17 1 2003 34
209. M. Noda, R.L. Vogel, A.M. Craig, J. Prahl, H.F. DeLuca, D.T. Denhardt Identification of a DNA sequence responsible for binding of the 1,25-dihydroxyvitamin D3 receptor and 1,25-dihydroxyvitamin D3 enhancement of mouse secreted phosphoprotein 1 (SPP-1 or osteopontin) gene expression Proc. Natl. Acad. Sci. USA 87 24 1990 9995